KKR Allocates $200 Mn to Boost India’s Medical Devices Manufacturing

The investment will be channelled primarily through Healthium Medtech, KKR’s India-based medical device platform.

Global Investment Company KKR & CO has announced the allocation of INR 1,650 crore and INR 1,700 crore (approximately $200 million) to deepen its footprint in India’s fast-growing medical devices industry, marking it one of the largest private equity bets in the country’s healthcare manufacturing space.

The investment will be channelled primarily through Healthium Medtech, KKR’s India-based medical device platform.

The new investment will support domestic manufacturing expansion, acquisitions, and export capability development.

The capital infusion will be used to acquire companies that complement Healthium’s existing portfolio and strengthen its product base in key areas such as surgical consumables, wound closure, orthopaedics, and advanced medical technology solutions.

This announcement follows the company's acquisition of Healthium for INR 7,000 crore.

KKR’s renewed focus on the Indian healthcare and medtech space follows its earlier successes with Healthium Medtech and Max Healthcare. It marks the firm’s re-entry into India’s medical devices sector after a lucrative exit in 2022.

Beyond medtech, KKR’s broader healthcare portfolio in India includes major investments in JB Chemicals and Pharma Ltd, Max Healthcare Pvt. Ltd, Healthcare Global Enterprises (HCG) Ltd, and Gland Pharma Ltd.

Stay tuned for more such updates on Digital Health News